1Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol, 2000, 43(6) :1049 - 1057.
2Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol, 2000, 42 ( 3 ) :422 - 427.
4Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasonecyclophosphamide pulse therapy in pemphigus. Dermatology, 2002,204(3) :228 -231.
5Brodsky RA, Petri M, Smith BD, et al. Immunoablative highdose cyclophosphamide without stem-cell rescue for refractor, severe autoimmune disease. Ann Intern Med, 1998, 129(12) :1031 -1035.
6Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vnlgaris. J Am Acad Dermatol, 2000, 43(6) :1065 - 1069.
7Takamori K. Recent advances in the treatment of autoimmune bullous diseases. J Dermatol, 2001, 28 ( 11 ) :654 - 657.
8Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol, 2002, 47 ( 3 ) : 358 -363.
9Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol, 2002, 138(9) :1158 - 1162.
10Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol, 2001,45 (5) :679 -690.
10Ikede S,Imamura S,Hashimoto L,et al.History of the establishment and revision of diagnostic criteria,severity index and therapeutic guidelines for pemphigus in Japan[J].Arch Dermatol Res,2003,295:S12-S16.
